Synaptic dopamine (DA) levels seem to affect the in vivo binding of many D2 receptor radioligands. Thus, release of endogenous DA induced by the administration of amphetamine decreases ligand binding, whereas DA depletion increases binding. This is generally thought to be due to competition between endogenous DA and the radioligands for D2 receptors. However, the temporal discrepancy between amphetamine-induced increases in DA as measured by microdialysis, which last on the order of 2 h, and the prolonged decrease in ligand binding, which lasts up to a day, has suggested that agonist-induced D2 receptor internalization may contribute to the sustained decrease in D2 receptor-binding potential seen following a DA surge. To test this hypothesis, we developed an in vitro system showing robust agonist-induced D2 receptor internalization following treatment with the agonist quinpirole. Human embryonic kidney 293 (HEK293) cells were stably co-transfected with human D2 receptor, G-protein-coupled receptor kinase 2 and arrestin 3. Agonistinduced D2 receptor internalization was demonstrated by fluorescence microscopy, flow cytometry, and radioligand competition binding. The binding of seven D2 antagonists and four agonists to the surface and internalized receptors was measured in intact cells. All the imaging ligands bound with high affinity to both surface and internalized D2 receptors. Affinity of most of the ligands to internalized receptors was modestly lower, indicating that internalization would reduce the binding potential measured in imaging studies carried out with these ligands. However, between-ligand differences in the magnitude of the internalization-associated affinity shift only partly accounted for the data obtained in neuroimaging experiments, suggesting the involvement of mechanisms beyond competition and internalization.
INTRODUCTION
Many studies have shown that acute fluctuations in synaptic dopamine (DA) affect the in vivo binding of D2 receptor radioligands used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) studies (for review, see Laruelle, 2000) . An increase in DA release, such as that induced by amphetamine administration, leads to an acute decrease in the in vivo binding of imaging ligands. Conversely, reducing DA release by DA depletion leads to an increase in the in vivo binding of the ligands. The recognition of this phenomenon in animals inspired the methodology to measure changes in synaptic DA in humans with SPECT using IBZM and with PET using raclopride. This methodology has been used extensively to study alterations in DA transmission in schizophrenia (Laruelle et al, 1996; Breier et al, 1997; Abi-Dargham et al, 2000) and substance abuse (Volkow et al, 1997; Martinez et al, 2007) , as well as the effects of stimulants on DA neurotransmission van Berckel et al, 2006; Volkow et al, 2009) .
The ability of neuroimaging ligands to report on changes in synaptic DA has been validated by two key observations. In humans, DA depletion blocks the effect of stimulants on the in vivo binding of PET radiotracers (Laruelle et al, 1997a) . In nonhuman primates, the magnitude of DA release, as measured with microdialysis, correlates with the decrease in D2 receptor-binding potential (BP, the ratio of receptor number to affinity, B max /K D ), as measured with PET or SPECT (Breier et al, 1997; Laruelle et al, 1997b) . These interactions have been reliably observed with moderate-to-high-affinity D2 receptor benzamide antagonists, [ 11 C] (Laruelle, 2000; Slifstein et al, 2004; Mukherjee et al, 2005; Riccardi et al, 2006; Cropley et al, 2008; Narendran et al, 2009 ), but inconsistently with the very-high-affinity D2 receptor antagonists, [ (Laruelle, 2000; Aalto et al, 2009; Narendran et al, 2009 ). This divergence may be due to physiochemical differences among the ligands, or because of the technical difficulties encountered in quantification of striatal D2 receptor availability with veryhigh-affinity ligands. Studies with the radiolabeled D2 receptor agonists, [ ]PHNO, have shown that the in vivo binding of these tracers is also sensitive to changes in synaptic DA (Narendran et al, , 2006 Ginovart et al, 2006) .
Although it is generally accepted that competition between D2 radioligands and endogenous DA affects the binding of ligands at D2 receptors, the temporal discrepancy between changes in DA levels and radioligand binding is not fully explained by the competition model. Following intravenous amphetamine administration, the increase in extracellular DA and behavioral activation lasts about 2 h (Ichikawa and Meltzer, 1992; Laruelle et al, 1997b) , whereas the in vivo decrease in D2 receptor BP measured with PET or SPECT ligands lasts about 4 to 24 h (Laruelle et al, 1997b; Carson et al, 2001; Narendran et al, 2007) . G-protein-coupled receptors (GPCRs), including D2 receptors, show agonist-induced internalization (Ito et al, 1999; Vickery and von Zastrow, 1999; Macey et al, 2004; Paspalas et al, 2006) , which might account for the temporal discrepancy (Laruelle, 2000) .
Like most GPCRs, D2 receptor internalization is regulated by GPCR kinases (GRKs) and arrestins (Ito et al, 1999; Kim et al, 2001; Macey et al, 2004; Heusler et al, 2008; Namkung et al, 2009) , which target the receptor to clathrin-coated pits for internalization (Tsao et al, 2001; Perry and Lefkowitz, 2002) . Agonist-induced internalization of D2 receptors would result in a reduction in BP if the B max or K D of the receptors for the ligands was reduced by internalization, which might be due to diminished ligand access or to changes in receptor conformation in the microenvironment associated with internalization.
To address the role of D2 receptor internalization in the readout of neuroimaging ligands, we developed an in vitro system to measure binding to surface and internalized D2 receptors independently. Human embryonic kidney 293 (HEK293) cells were stably transfected with D2 receptors (Javitch et al, 2000) tagged with enhanced yellow-fluorescent protein (EYFP), and co-transfected with GRK2 and arrestin 3 to foster robust D2 receptor internalization. We demonstrate that these cells show robust D2 receptor internalization, allowing us to address the effect of receptor internalization on the binding of the most-used neuroimaging ligands.
MATERIALS AND METHODS

Cell System
T-REx-293 cells, a Tetracycline-Regulated Expression cell line (Invitrogen, Carlsbad, CA, USA), were grown in Dulbecco's modified Eagle's medium (GIBCO) containing 10% fetal calf serum and 5 mg/ml blasticidin at 371C with 5% CO 2 , and passaged weekly. The bovine GRK2 and rat arrestin 3 cDNAs were subcloned into T-REx expression plasmids pcDNA4/TO and pcDNA5/TO (Invitrogen), respectively, and confirmed by sequencing. The human short isoform of D2 receptor (D2S) cDNA with a FLAG epitope at the amino terminus was fused with EYFP at the carboxyl terminus and subcloned into the bicistronic expression vector pCIN4 (Rees et al, 1996; Javitch et al, 2000) . The constructs pcDNA4-GRK2 and pcDNA5-arrestin 3 were serially co-transfected into the T-Rex-293 cells using lipofectamine (Invitrogen). Zeocin-and hygromycin-resistant cells were selected. GRK2 and arrestin 3 expression was examined by immunoblotting following tetracycline induction (see below). The construct pCIN4-D2S was then transfected into the stable doubly transfected cells, and the triple-transfected cells were selected in the presence of 700 mg/ml G418, in addition to hygromycin, Zeocin, and blasticidin.
Western Blot Analysis
Control T-REx-293 and the triple-transfected cells were treated with tetracycline or vehicle for 24 h, and then solubilized with 1% dodecyl maltopyranoside in phosphatebuffered saline (PBS) buffer (11 mM Na 2 HPO 4 , 154 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , 0.1 mM CaCl 2 , 2 mg/ml pefabloc, 2 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin A, and 10 mM N-ethylmaleimide). Protein lysates (20 mg) were separated by SDS-PAGE using a 7.5% polyacrylamide gel and transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA). Membranes were blocked for 30 min at room temperature with 5% nonfat milk, 1% bovine serum albumin (BSA), 0.1% Tween 20 in Tris-buffered saline (TBST; 50 mM TrisHCl, 150 mM NaCl, pH 7.4). Primary antibodies, anti-GRK2 rabbit polyclonal (1 : 1000, Santa Cruz Biotechnology), antiarrestin 3 rabbit polyclonal (1 : 500, Sigma-Aldrich), and anti-FLAG rabbit polyclonal (1 : 10 000, Sigma-Aldrich) were incubated with the PVDF membranes at room temperature for 1 h to detect GRK2, arrestin 3, and D2 receptor, respectively. Membranes were then washed three times for 10 min each with TBST, incubated with horseradish peroxidase-conjugated anti-rabbit-antibody (1 : 15 000, Santa Cruz Biotechnology) at room temperature for 1 h, and washed three times. Immunoblots were treated with ECLPlus reagent (Amersham Biosciences, Piscataway, NJ); proteins were visualized and quantitated on a FluorChem 8000 (Alpha Innotech Corporation, San Leandro, CA).
Drug Treatment
Tetracycline. Triple-transfected cells were grown in 100-mm culture dishes for 3-5 days until they were 80-90% confluent. To induce expression of GRK2 and arrestin 3, tetracycline was added to the cells (T + ) at a final concentration of 1 mg/ml for 24 h at 361C. Control cells (TÀ) were incubated with the same volume of vehicle solution.
Quinpirole. To induce D2 receptor internalization, tetracycline-treated (T + ) and control (TÀ) cells were incubated D2 receptor internalization and ligand binding N Guo et al with quinpirole (T + /Q + ; TÀ/Q + ) at a final concentration of 30 mM for 3 h at 361C. Control cells (T + /QÀ, TÀ/QÀ) were incubated with vehicle. After quinpirole treatment, the medium was removed and the cells were washed with 10 ml PBS (pH 7.4) at 41C and used in the immunolabeling or radioligand-binding procedures as described. As neither tetracycline alone nor basal expression of GRK2 and arrestin 3 affected D2R internalization, all radioligand binding studies were carried out on tetracycline-treated cells.
MTSET. The sulfhydryl-specific reagent [2-(trimethylammonium)ethyl] methanethiosulfonate bromide (MTSET) is a membrane-impermeant, positively charged polar molecule that reacts with the sulfhydryl group of Cys114 in the binding-site crevice of the D2 receptor to inhibit ligand binding (Javitch et al, 1994 (Javitch et al, , 2000 . MTSET was used to inactivate cell surface D2 receptors selectively. Aliquots of control and quinpirole-treated cell suspensions (100 ml) were incubated with freshly dissolved MTSET at final concentrations of 0.03-10 mM at 41C for 15 min. In competition and saturation binding studies, cells were incubated with 5 mM MTSET. The reaction was slowed by addition of cold binding buffer to the cell suspensions to a final volume of 500 ml (see below).
Immunohistochemistry and Flow Cytometry Quantification
To visualize internalization, cells were washed three times with ice-cold HEPES saline buffer (25 mM HEPES, 140 mM NaCl, 5.4 mM KCl, 10% goat serum, pH 7.4). An anti-FLAG labeling mixture was prepared by adding 5 mg Zenon-Alexa 647 mouse IgG labeling reagent A (Invitrogen) to 0.4 mg anti-FLAG antibody in 15 ml PBS (without Ca 2 + and Mg 2 + ) at room temperature for 5 min, then adding 5 mg IgG labeling reagent B, and incubating for 5 min, adjusting the total volume to 100 ml by adding 10% goat serum in HEPESbuffered saline. For fluorescence microscopic imaging, we applied the labeling mixture to cells grown in microwell dishes (MatTek, Ashland, MA) and incubated for 40 min at 41C. Cells were washed with HEPES-buffered saline three times, and viewed using an Axiovert 35M (Zeiss). Digital images were captured (Photometrics Sensys camera, Roper Scientific, Tucson, AZ) with iVision software (BioVision, Exton, PA). Sequential imaging was carried out using a diamond objective scriber to mark the regions of interest. Zenon-fluorescence labeling identified surface D2 receptors, and EYFP labeling identified both surface and internalized receptors.
For flow cytometry, dissociated cells were incubated under the same conditions. Surface receptors were labeled using the transfected D2 receptor N-terminal FLAG-tag with anti-FLAG-mouse and anti-mouse-PE antibodies (Invitrogen) diluted 1 : 500 in PBS (with 0.1% of BSA and 0.1% of NaN 3 ), and quantitated using a Guava EasyCyte (Millipore).
Radioligand Binding
Whole-cell suspension. Cells were dissociated by gentle trituration in 3 ml of binding buffer (25 mM HEPES, 140 mM NaCl, 5.4 mM KCl, 0.006% BSA, 1 mM EDTA, pH 7.4) at 41C, counted with a hemocytometer, and diluted with cold binding buffer to make the cell suspension of 1.9 Â 10 6 -2.8 Â 10 6 cells/ml. To reduce oxidation of DA and D2 agonists in competition binding assays, 0.1% ascorbic acid was added to the binding buffer. H]raclopride (1.5 nM) and competitors, including the imaging agents (raclopride, IBZM, NMSP, fallypride, FLB 457, epidepride, PHNO and NPA) and control agents (quinpirole, dopamine and sulpiride). Nonspecific binding was determined in the presence of 10 mM (+)-butaclamol. Each binding experiment was carried out in duplicate, and the reaction mixtures (final volume 500 ml) were vortexed and then incubated at 41C for 3.5 h. The incubation was terminated by rapid filtration on a Cell Harvester (Brandel, Gaithersburg, MD) through GF/B filters pretreated with 0.3% polyethyleneimine. The filters were washed four times with ice-cold Tris-HCl buffer (10 mM Tris-HCl, 120 mM NaCl, pH 7.4), and the radioactivity on the filters was counted with a scintillation counter (Packard, Meriden, CT). The competition curves were analyzed by comparison of two-site vs onesite binding models with nonlinear curve fitting (Prism 4, GraphPad Software, San Diego, CA).
Saturation binding. Following MTSET treatment, which blocks binding of ligands to surface D2 receptors, cells (100 ml) were incubated with six concentrations of [ 
RESULTS
Tetracycline-Induced GRK2 and Arrestin 3 Expression
T-REx-293 cells stably expressing D2-EYFP receptors were engineered for tetracycline-induced expression of GRK2 and arrestin 3 to facilitate robust agonist-induced D2 receptor internalization. Both control T-REx-293 and triple-transfected cells showed low basal expression of GRK2 and arrestin 3 ( Figure 1a ). Tetracycline increased GRK2 and arrestin 3 expression dramatically, with 190 ± 24% increases in GRK2 (n ¼ 3) and 538 ± 75% in arrestin 3 (n ¼ 2) expression in the triple-transfected cells, compared with untreated cells.
D2 receptor internalization and ligand binding N Guo et al
Visualization of D2 Receptor Internalization
Monolayers of triple-transfected cells were examined when they were close to confluence ( Figure 1b1 ). The enhancement of GRK2 and arrestin 3 expression resulted in robust agonist-induced D2 receptor internalization. Under control conditions (without tetracycline or quinpirole, or tetracycline alone, D2 receptors were mainly expressed on the cell surface, as indicated by the surface fluorescence of EYFP-tagged D2 receptors (QÀ, Figure 1b2 ). Following tetracycline induction and quinpirole treatment, EYFPlabeled receptors shifted to the cytoplasm, forming a characteristic punctate endocytic distribution (Q + , Figure  1b3 ). As neither tetracycline nor quinpirole alone induced D2 receptor internalization, cells were pretreated with tetracycline in all subsequent imaging and binding experiments, and internalization was induced by quinpirole.
Quantitation of Internalization with Flow Cytometry
To detect internalization, we used Zenon-labeled anti-FLAG Fab fragments directed to the FLAG epitope on the extracellular D2 receptor N-terminus. Under control conditions, nearly all D2 receptors were located on the surface, as the EYFP fluorescence (visualized in red) and Zenon fluorescence (visualized in green) overlapped (appearing yellow), outlining the plasma membrane ( Figure 2a1 ). Following quinpirole treatment, surface labeling diminished (less yellow), and many receptors were internalized, appearing in a punctate intracellular pattern (red) ( Figure 2a2 ). We used flow cytometry to quantify internalization by analyzing anti-FLAG labeling of surface receptors ( Figure 2b ). An example of the distribution of fluorescence intensity for surface D2 receptors before (black) and after (red) quinpirole administration is shown in Figure 2b1 . Timecourse studies revealed maximal D2 receptor internalization of about 58% following quinpirole treatment with a t 1/2 of about 5 min (Figure 2b2 ). Figure 1 Visualization of GRK2-and arrestin 3-enhanced quinpiroleinduced D2 receptor internalization. T-REx-293 cells were triple transfected with D2 receptors, with a FLAG epitope on the extracellular N-terminus and yellow-fluorescent protein (YFP) on the intracellular C-terminus of D2 receptors, GRK2, and arrestin 3 (Arr3). (a) Immunoblot analysis of preparations from T-REx-293 control and D2-GRK2-Arr3 tripletransfected cells. Tetracycline had no effect on the basal expression of GRK2 and arrestin 3 in control T-REx-293 cells (left), while it induced robust expression of GRK2 and arrestin 3 in the triple-transfected cells. GRK2 and arrestin 3 proteins were detected by polyclonal anti-GRK2 and anti-arrestin 3 antibodies, respectively. (b) Cells were treated with tetracycline and then viewed under DIC optics (b1) or epic-fluorescence (b2), and then again following quinpirole treatment (b3). Under control condition (QÀ), D2 receptors were mainly expressed at the cell surface, as indicated by the surface fluorescence labeling of Zenon anti-FLAG and D2 receptor-YFP fluorescence (b2). Quinpirole (Q + ) induced a dramatic redistribution of EYFP fluorescence into a punctate intracellular pattern, reflecting robust D2 receptor internalization (b3). Cells moved significantly during the quinpirole incubation so the fluorescence images are not directly super imposable. Figure 3b ). Because sulpiride is relatively impermeant due to its fixed negative charge (Mizuchi et al, 1983; Honda et al, 1977) , the highaffinity sites presumably correspond to surface D2 receptors (Ki (s) ) and the low-affinity sites to internalized D2 receptors (Ki (i) ). Following quinpirole treatment (Q + ), 55% of D2 receptors retained high affinity (Ki (s) ¼ 9.4±2.6 nM), whereas 45% showed low affinity (Ki (i) ¼ 142.9 ± 26.3 mM), indicating that about 35% of receptors underwent internalization (Figure 3b) .
[ 3 H]raclopride binding and raclopride competition. Due to its lower lipophilicity compared with NMSP, raclopride was expected to have more limited access to internalized D2 receptors (Laruelle, 2000 
Impact of Internalization on Ligand Affinity
The experiments described above showed that most D2 receptors are at the cell surface under basal conditions, whereas about 40% of D2 receptors are internalized following quinpirole treatment, and that [ 3 H]NMSP binding curve; the majority of D2 receptors (90%) were accessible to sulpiride and thus subject to competition at high affinity (Ki (s) ¼ 9.1±1.0 nM), whereas only a small minority (10%), presumably internalized, were relatively inaccessible and hence subject to competition at low affinity (Ki (i) ¼ 142.5 ± 26.8 mM). Following quinpirole treatment (K, Q + ), the high-affinity [ 3 H]NMSP binding was reduced to 55%, whereas the low-affinity binding increased to about 45%, consistent with robust D2 receptor internalization. Competition with D2 antagonists and agonists. Using Table 1 ). In contrast, competition with raclopride showed similar one-site binding curves under both control and internalization/surface D2R-inactivation conditions (Figure 6b) . Consistent with the saturation binding, raclopride competition also showed a small but significant increase in Ki value in MTSET-treated cells following quinpirole (Figure 6b ; Table 1 ). Similarly, all tested antagonist imaging ligands (Supplementary Figure S1 , Supplementary Information) were able to compete at internalized receptors with high affinity. A small but significant increase in the Ki value for quinpirole plus MTSET-treated cells was observed in competition with NMSP ( Figure S2B ), but not NPA nor the control agent quinpirole (Table 1 ; Supplementary Figure SA2 , S2C); all were able to compete at internalized receptors with high affinity. In contrast, DA (Table 1 ; Supplementary Figure S2D ), which similar to sulpiride diffuses poorly into cells, showed a dramatic reduction in binding to internalized receptors. For the seven imaging agents, a two-way ANOVA on Ki value under the control and internalization/membrane D2R-inactivation conditions (QÀ/MTSETÀ vs Q + /MTSET + ), with ligands as factors revealed a significant effect of condition (p ¼ 0.003), ligands (po0.001) and condition by ligands interactions (po0.001). Thus, internalization was associated with a small but significant loss of affinity overall. The magnitude of the effect varied among the ligands tested. Post hoc analysis carried out on normalized values revealed that the internalization effect was significantly larger for fallypride and FLB 457, compared with IBZM and NPA, but not significantly different from the other ligands.
DISCUSSION
We examined the impact of D2 receptor internalization on the binding affinities of D2 receptor antagonists and agonists commonly used in PET and SPECT imaging studies. Initial experiments in T-REx-293 cells stably transfected with D2 receptors failed to show reliable agonist-induced D2 receptor internalization. Under baseline and following agonist treatment, 490% of D2 receptors remained on the cell surface. In contrast, cells cotransfected with GRK2 and arrestin 3 showed robust agonist-induced internalization, confirming that GRK2 and arrestin 3 have critical roles in agonist-induced D2 receptor internalization (Ito et al, 1999; Kim et al, 2001; Macey et al, 2004; Heusler et al, 2008; Namkung et al, 2009 ). Quantification of agonist-induced internalization in triple-transfected cells yielded consistent results with four independent methods: flow cytometry (58% internalized fraction), MTSET inactivation (40%), saturation binding (35% with 3 H-NMSP; 43% with 3 H-raclopride), and sulpiride competition (51% with This cellular system provided a straightforward way to compare the affinity of unlabeled ligands for surface and internalized receptors. The affinity measured under basal conditions (QÀ/MTSETÀ) was the affinity at surface receptors, whereas the affinity measured after quinpirole exposure and MTSET inactivation (Q + /MTSET + ) was the affinity at internalized receptors. Comparing [ Loc'h et al, 1996) Epidepride (6) 0.01 ± 0.01 0.03 ± 0.01* 2.4 2.1 z (Kessler et al, 1991) Fallypride (6) 0.32 ± 0.06 0.92 ± 0.31** 2.9 2.4 w (Laruelle, 2000) IBZM (9) 0.19±0.05 0.23±0.11 1.2 2.8 w (Laruelle, 2000) NMSP (6) 0.07 ± 0.01 0.13 ± 0.02** 1.9 3.3 w (Laruelle, 2000) Agonist PHNO (9) The average decrease in affinity associated with internalization for all the imaging ligands was 2.1 fold. A change of this magnitude would have a direct impact on neuroimaging results. BP is the measured binding parameter and is inversely proportional to
Assuming, for the sake of argument, that all D2 receptors are on the surface under baseline conditions, and that 50% of receptors are internalized following an amphetamineinduced DA surge, then BP would be reduced by 25%. The magnitude of this decrease is comparable with the BP decrease observed following an amphetamine challenge in vivo (Laruelle et al, 1997b) .
There are several potential caveats that need to be considered in the interpretation of our competition studies. Incomplete washout of quinpirole could have led to a reduction in the apparent affinity determined in saturation binding analysis after internalization, but the similarity between our saturation and competition results suggest that this is not a confound. The free ligand concentration in the vicinity of internalized receptors might be lower than in the extracellular milieu because of the time required for ligands to traverse the plasma and endosomal membranes to reach internalized receptors. The existence of a gradient between extracellular ligand and endosomal ligand concentrations could give rise to an apparent increase in the Ki value measured in the competition experiments. And, difficulties in diffusion into cells evidently do translate into changes in apparent affinity, as exemplified by the sulpiride and DA experiments. However, we carried out our studies under quasi-equilibrium conditions in an attempt to obviate differences in free ligand concentration across the membrane. Regardless, this should not affect the implications for neuroimaging studies in which the extracellular concentration is used as the reference concentration to calculate K D and BP. Changes in binding affinity revealed here should thus parallel the changes in BP observed in neuroimaging studies.
Overexpression of arrestin 3 could alter the affinity of D2 receptors for some ligands and a difference between arrestin binding to surface and internal receptors could conceivably contribute to our findings. Indeed, arrestin 3 binding to purified b 2 -adrenergic receptors substantially increases agonist affinity (410-fold) (Gurevich et al, 1997) . However, we did not see a consistent effect on the binding of agonists, which should be affected similarly by receptor affinity state; PHNO showed a reduced affinity for internalized receptors, while NPA and quinpirole were unaffected. Therefore, it seems unlikely that binding of arrestin 3 would impact significantly on the binding affinity in our system.
We measured the changes in affinity of internalized D2 receptors 3-4 h after triggering internalization and at 41C to prevent receptors from recycling back to the plasma membrane. It is not known how rapidly or how many D2 receptors recycle back to the membrane in vivo. In HEK-293 cells, at 371C, D2 receptors degrade slowly (t 1/2 47 h) but recycle rapidly back to the membrane (t 1/2 430 min) (Vickery and von Zastrow, 1999) . It seems likely that significant numbers of receptors recycle back to the membrane during the course of a neuroimaging experiment. However, this would lessen (rather than magnify) the contribution of internalization to the extent and duration of decreases in BP of radoiligands in neuroimaging studies. Finally, it remains possible that the T-REx-293 cells we used do not entirely model the differences in neurons in the receptor microenvironment associated with internalization. This issue will require further studies in neurons.
Constrained by these limitations, the results described in this paper have implications for the interpretation of D2 neuroreceptor imaging studies. We show that all the tested imaging ligands bind with high but different affinity to surface and internalized receptors. The implication is that the specific binding of ligands observed in PET and SPECT imaging studies is a mixture of binding to surface and internalized receptors. As several of the ligands show different affinities for D2 receptors based on internalization status, changes in D2 receptor BP observed in pathological conditions may be due to differences in internalization status. The results generally support the hypothesis that changes in internalization status following interventions that modulate synaptic DA concentrations contribute to changes in observed BP. As addressed in the Introduction, changes in BP persist well beyond acute fluctuations in extracellular DA concentrations, suggesting that mechanisms other than simple binding competition contribute to the sustained BP decrease following a DA surge. Decreased affinity of internalized receptors might be one such mechanism. One way to test this hypothesis would be to correlate the time course of changes in cellular localization of D2 receptors in vivo with the time course of changes in BP following a DA surge.
The differences between ligands in the magnitude of the affinity shift associated with internalization status were not related to differences in affinity, lipophilicity, chemical nature, or pharmacological property (agonists vs antagonists). Furthermore, they were not directly related to the magnitude of changes in in vivo binding following manipulation of DA release. (Laruelle, 2000; Slifstein et al, 2004; Mukherjee et al, 2005; Riccardi et al, 2006; Cropley et al, 2008; Narendran et al, 2009 ). The differences in affinity shifts among the three ligands induced by internalization (fallypride4raclopride4IBZM) observed here suggest that the affinity shift is not the only factor contributing to the long lasting BP changes observed in neuroimaging experiments. Changes that would affect the B max in the brain without changing the affinity, such as receptor modification or degradation, might not be captured by these results. Further study will be needed to test these putative factors.
The vulnerability of [ 11 C]NPA to changes in endogenous DA is larger than that of [ 11 C]raclopride, an observation that has been attributed to fact that [ 11 C]NPA, being a full agonist, binds preferentially to D2 receptors in the highaffinity state, a population of receptors expected to be more affected by changes in synaptic DA . The difference in affinity shift induced by internalization between these ligands (raclopride4NPA) seen in these studies does not jive with the magnitude of BP decrease ([ (Narendran et al, 2006; Rabiner et al, 2009 ). In the experiments reported here, the affinity shift of PHNO was numerically larger than for NPA, an observation inconsistent with internalization alone accounting for the results of the imaging studies.
Interpreting the results for the very-high-affinity antagonists, [ receptors BP with these ligands in high D2 receptor density regions such as the striatum is practically impossible due to the protracted time required for these ligands to reach equilibrium and the vulnerability of their uptake to changes in blood flow. Many contradictory studies have thus been reported in the literature; studies with [ 11 C]NMSP or analogs reported increased, decreased, or no change in BP following amphetamine (Leslie and Bennett, 1987; Bischoff et al, 1991; Bischoff and Gunst, 1997; Hartvig et al, 1997) . Two studies with [
123 I]epidepride suggested no changes in BP following amphetamine (Al-Tikriti et al, 1994; Tibbo et al, 1997) . From a kinetic point of view, [ , 2009) ; however, such a change was not found by others (Okauchi et al, 2001; Aalto et al, 2009) . The low signal-to-noise associated with measurement of cortical D2 receptors might explain this discrepancy. Because of the uncertain nature and magnitude of the vulnerability of these ligands to endogenous DA in imaging paradigms, only a limited comparison with these results is possible.
In conclusion, we have developed an in vitro system suitable for independent measurements of the affinity of ligands to surface and internalized D2 receptors. Testing of eight commonly used D2 receptor neuroimaging ligands showed that all ligands bind with high affinity to both surface and internalized receptors. Receptor internalization is associated with a small but significant reduction in binding affinity for six of the eight ligands. To the extent that these findings can be extrapolated to the in vivo condition, our results suggest that D2 receptor trafficking may affect the signal measured in neuroimaging studies and may have a role in the sequence of events leading to changes in D2 receptor BP following subsequent to fluctuations in synaptic DA concentrations. However, differences in affinity shifts among the ligands suggest that additional factors beyond receptor trafficking are likely to be involved in these long-lasting changes. Further study will be needed to determine the role of receptor trafficking in these responses, as well as to identify and validate other mechanisms.
